# Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

> **NCT00036127** · PHASE2,PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.**

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** aripiprazole

## Key facts

- **NCT ID:** NCT00036127
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036127, "Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00036127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*